drugset / Trial / NCT07561645

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

NCT07561645

Phase 2 Not yet recruiting 75 enrolled Technical University Dresden
NaSingle-groupOpen-labelTreatment

Summary

This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.

Timeline

Start
2026-07
Primary completion
2032-04
Completion
2032-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Obrixtamig Other / unclassified